Tag Archives: 2020

Live webcast on masitinib in combination with isoquercetine for the treatment of COVID-19 on Monday May 11, 2020

07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020  

Authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19

06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19

Annual financial results as of 31 December, 2019

30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019

Letter to our stakeholders on COVID-19 pandemic impact on AB Science studies

03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies

New fundraising of EUR 12.3 million

02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million

Positive top-line Phase 2B/3 results for masitinib in progressive forms of MS

20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis

FDA green-lights U.S. patient enrollment in masitinib phase 3 study in metastatic castrate-resistant prostate cancer

08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy